Kharif 2026: India's farmer kept buying. Our industry stopped earning. - Raju Kapoor, Founder, Elan Growth Advisors

By: Raju Kapoor

Last updated : November 17, 2026 6:42 am



Q2 FY27 results show demand intact, margins under siege and a rare opening for Indian companies willing to invest


All ten listed Indian crop protection companies have now reported results for July–September 2026, the second quarter of FY27. Read together, they carry a message our industry cannot afford to ignore. The Indian farmer did not stop buying. We stopped earning.

That distinction matters. A demand problem calls for patience; an earnings problem calls for change. This season gave us the second, and with it a chance to reshape the industry for the decade ahead.

Trend 1: Demand was delayed, not lost

The monsoon arrived late, not never. Spraying that should have happened in April–June moved into July–September. Dhanuka's revenue swung from a 13% decline in the first quarter to 10% growth in the second; Insecticides India moved from –10% to +8%. Over the half year, domestic players are broadly flat: Rallis up 3%, Sumitomo Chemical India and Dhanuka down 1% each. Channel inventory is lean, the healthiest starting point the trade has had in some time.

Trend 2: Margins, not volumes, carried the pain

Six of the nine companies that disclose EBITDA reported narrower margins. Raw-material inflation, partly driven by tension in the Middle East, could not be passed on to a cautious trade channel. Rallis' margin fell to 14.7% from 17.9%; Sumitomo's to 20.5% from 23.5%. The squeeze was not ours alone. Paradeep Phosphates grew revenue 7% while profit fell 65%. Escorts Kubota grew revenue 16% and profit fell 21%. Coromandel's crop protection business grew 22%, yet group profit dropped 34% as fertiliser input costs outran subsidy. Across agri inputs the pattern is the same: revenue up, profit down.

Trend 3: The divide is between business models

India-based exporters were hit hardest. PI Industries' EBITDA fell 57% and its margin more than halved, to 13.9% from 29.0%, as agrochemical exports dropped about 18%. Sumitomo's exports fell 23% as its parent destocked. Companies selling across continents absorbed India's weather shock. UPL lifted EBITDA 5% and widened its margin to 19.5%. Sharda Cropchem grew profit 23% on 30% growth in North America and 80% in Latin America, offsetting drought in Europe. Geography, not size alone, decided who held up.

Trend 4: Headline profit is misleading

Tax, insurance and currency items distort reported earnings this year. DCM Shriram's half-year profit includes a ₹474 crore tax gain; Sumitomo's includes a ₹27 crore insurance receipt. UPL's attributable profit fell 24% on finance costs and translation losses even as its operations improved. Even the analysts misread the quarter: Nuvama expected EBITDA to fall 56% at Coromandel and 36.7% at PI. The actual declines were 18% and 57%. Boards and investors should judge this cycle on EBITDA and cash flow.

THREATS 

Generic oversupply: Competition on off-patent molecules is a race to the bottom, and exporters competing on price alone will keep losing margin. Syngenta Group's July–September sales fell 10% to $5.2 billion on delayed purchases and Latin American generic pricing.

The weather: Two disrupted kharif seasons in a row make the monsoon a business variable, not an act of God. Low reservoirs and El Niño are the near-term risks to rabi, with rice most exposed. Dhanuka already expects a subdued third and fourth quarter.

Working capital: Insecticides India's working capital stood at 158 days and Sumitomo's inventory at 115 days. When collections slow and costs rise together, balance sheets decide who can keep investing.

A weak farm-input ecosystem: Rallis' seeds business fell 31%, DCM Shriram's Bioseed 15% and Kaveri Seed's half-year revenue 10%. Seeds, nutrients and crop protection rise and fall together.

OPPORTUNITIES

Global majors are restructuring: FMC, after a $2.07 billion third-quarter loss, is selling its India commercial business. BASF is demerging its agri arm in India, whose segment swung to a Rs. 29 crore loss from a Rs. 50 crore profit. Syngenta is shedding low-margin lines. Market share, distribution and talent will change hands over the next two years. Indian companies that invest now in brands, research and farmer reach can capture them.

Innovation already pays: PI's domestic biologicals grew 45%. Best Agrolife raised profit 48% on a 21% fall in revenue by lifting its branded share to 81% from 69%. Premium formulations held margins where generics could not.

Exports need not be a price game: India can move up the value chain through patented chemistry, contract development and manufacturing, and trusted, compliant production for global partners. UPL and Sharda show that Indian companies can be global champions. We need many more.

WHAT MUST BE DONE

For industry: Differentiate or be squeezed. Shift portfolios toward new molecules, biologicals and branded formulations. Plan for a less reliable monsoon with flexible supply chains and leaner channel inventory. Treat cash as seriously as revenue.

For policymakers: Faster registration of new molecules, timely notification of nutrient-based subsidy rates and predictable input-cost pass-through would unlock investment now on hold. Fertiliser makers show what happens when costs move faster than policy.

For investors: Separate cyclical pain from structural pain. Weather-driven volume losses reverse; export pricing pressure from generic oversupply will take longer to ease.

The ROAD AHEAD The second half will be subdued but stable, with rabi the swing factor. Guidance will be tested: UPL needs a stronger second half to reach 7–11% revenue growth, while Sharda has held to 10–15%.

The larger story is structural. Indian agriculture needs more crop protection, not less, to feed a growing population from climate-stressed land. The companies, and the policies, that back innovation today will build the industry a Viksit Bharat needs by 2047. Kharif 2026 has shown us the pressure points. The question is whether we use this moment to fix them.

(Raju Kapoor is Founder, Élan Growth Advisors, and former Director – Corporate Affairs, FMC India. Views are personal. Figures are from company filings for Q2 FY27 (unaudited).)

 

Raju Kapoor Élan Growth Advisors FMC India Rallis India agrochemical PI Industries Innovation Best Agrolife molecules formulations biologicals subsidy supply chian exports BASF UPL Ltd. Sharda Cropchem Syngenta

First Published : November 17, 2026 12:00 am